MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: breast cancer features effectively assessed in real time by surgeons and pathologists using Cellvizio

Transparency directive : regulatory news

10/09/2015 18:07

PRESS RELEASE

   BREAST CANCER FEATURES EFFECTIVELY ASSESSED IN REAL TIME BY SURGEONS AND
                          PATHOLOGISTS USING CELLVIZIO

* Two studies support use of endomicroscopy to identify cancerous and healthy
           tissue in real time during breast conserving surgery

Paris, September 10, 2015 - Mauna Kea Technologies (Euronext: MKEA,
FR0010609263, PEA-SME eligible), inventor of Cellvizio(r), the multidisciplinary
confocal laser endomicroscopy platform, today announced the publication of
clinical study results involving the use of CLE with Cellvizio in the peer
reviewed journal Breast Cancer Research and Treatment. In the study, a research
team from Imperial College London investigated  the ability of probe-based
confocal laser endomicroscopy (pCLE) to image the morphology of neoplastic and
non-neoplastic breast tissues.

Current technologies to assess tumor excision during breast conserving surgery
are unable to provide real-time direct cytopathological imaging assessment of
the internal cavity walls within the breast. In addition to studying the ability
of pCLE to image the morphology of neoplastic and non-neoplastic breast tissues,
the authors also assessed the ability to differentiate these images among both
pathologists and surgeons. In the study, 71 freshly excised tumor samples and
adjacent non-diseased sections from 50 patients were imaged using pCLE. All
discernible pCLE features were cross-examined with conventional histopathology.
Following pattern recognition training, a group of nine pathologists and eight
surgeons with no prior pCLE experience interpreted 850 pCLE images
independently. A total of 350 pCLE image mosaics were also analyzed. The mean
accuracy of pCLE image interpretation among pathologists and surgeons was 94%
and 92%, respectively.

"In this study, the morphological features of neoplastic and non-neoplastic
breast tissues were readily visualized and distinguished with a very high degree
of accuracy by both histopathologists and surgeons," said Prof Guang-Zhong Yang,
Director of the Hamlyn Centre, Imperial College, London. "These findings provide
strong additional support for the potential use of pCLE to provide a real time,
accurate diagnosis of breast cancer during breast conservation surgery."

Results from an earlier study of the use of pCLE as a real-time diagnosis of
breast cancer were published in April 2015 in the peer-reviewed journal BMC
Cancer. In this study, use of pCLE revealed unique morphological patterns in
normal breast tissue, benign lesions and breast cancers. Histopathology
confirmed the presence of a benign lesion in six patients (46%) while breast
cancer was accurately diagnosed in seven women (54%). pCLE was able to
characterize several types of benign and malignant tissue. Approximately 700,000
lumpectomies are performed every year globally.

"The results of these recent studies on the use of Cellvizio for the first time
in breast cancer add to the rapidly expanding body of literature confirming the
potential opportunities to use our unique technology perioperatively in order to
rapidly and accurately identify the presence and the extent of cancer in real
time, potentially leading to more successful interventions and more targeted and
appropriate treatment for millions of patients each year," said Sacha Loiseau,
founder and CEO of Mauna Kea Technologies.

Next press release: Q3 2015 sales on October 15, 2015 (after close of trading)

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on protecting
patients' lives while enabling physicians and surgeons to make better decisions
thanks to direct visualization at the cellular level. The Company's flagship
product, Cellvizio, has received clearance to sell a wide range of applications
in more than 40 countries, including the United States, Europe, Japan, China,
Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit
www.maunakeatech.com

Mauna Kea Technologies
Eric Cohen
Vice President Finance
Tel: +33 (0)1 70 08 09 70
investor-vpf@maunakeatech.com

France and Europe
NewCap - Investor Relations | Strategic Communication
Florent Alba/Pierre Laurent
Tel: +33 (0)1 44 71 94 94
maunakea@newcap.fr

MAUNA KEA TECHNOLOGIES's latest news

02/11/2023 08:00

MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: breast cancer features effectively assessed in real time by surgeons and pathologists using Cellvizio

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories